PhRMA Teams With Provider And Patient Groups In Suit Against IRA Filed In Texas District Court
Executive Summary
Complaint seeks permanent injunction to require drug pricing program to give stakeholders opportunity to comment on the process and make decisions subject to judicial review.
You may also be interested in...
Stealth Defense: Medicare, IRS Implementation May Weaken Pharma’s Arguments Against IRA
Flexibility included in guidance issued after many IRA lawsuits were filed put some of the arguments industry has made on shakier footing, legal experts explain.
Industry's Suits Against Medicare Price Negotiation: Consolidation And Expansion
With a new suit from Boehringer Ingelheim and a consolidated schedule for other cases, the legal threats to the US Medicare drug price negotiation program mandated under the Inflation Reduction Act (IRA) become clearer. Our tracker keeps you apprised of the latest developments.
Industry's Suits Against Medicare Price Negotiation: Consolidation And Expansion
With a new suit from Boehringer Ingelheim and a consolidated schedule for other cases, the legal threats to the US Medicare drug price negotiation program mandated under the Inflation Reduction Act (IRA) becomes clearer. Our tracker keeps you apprised of the latest developments.